Healthy volunteers test new tablet form of autoimmune drug
NCT ID NCT06342700
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This Phase 1 trial enrolled 28 healthy adults to compare how two different tablet forms of rilzabrutinib (a drug for autoimmune disorders) are absorbed by the body, both with and without food. Participants received single doses of each form in a random order, with a day between doses. The study aims to see if a new crystalline tablet works as well as the current amorphous version, but does not test any treatment for disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nucleus Network Site Number : 8400001
Saint Paul, Minnesota, 55114, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rilzabrutinib (a drug being tested for autoimmune disorders)
What this could lead to
If successful, this study could help determine the best tablet form of rilzabrutinib for future trials, potentially leading to better treatments for autoimmune diseases.
What could go wrong
This is an early-phase study in healthy volunteers, not patients. It only measures how the drug is absorbed, not whether it works for any disease. Results may not predict real-world effectiveness.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.